Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 November 2020 | Story Ruan Bruwer | Photo Varsity Sports
Lefébre Rademan, the country’s top student netball player in 2019, has been snatched up by English netball club London Pulse to play in England in 2021.

 

Attempting to become an even better netballer, former Kovsies netball captain Lefébre Rademan decided to jet off to England to play in their league.

Rademan was contracted by London Pulse to compete in the European Superleague in 2021. She will be the fourth Kovsie after Maryka Holtzhausen (2015 and 2018-2019), Karla Pretorius (2016), and Khanyisa Chawane (2020) to play in the league.

Rademan said it was an easy decision, even though it will be far and a long time away from home. The league runs from February to July, with a pre-season in December. She will continue with her master’s degree at the University of the Free State next year.

“I am not going to play netball forever and such an opportunity doesn’t come often. Having competed against England, New Zealand, and Jamaica earlier in the year, I realised they play at a much higher level and if I want to improve and become the best, I would also need to move to a next level.”

“As a goal attack, having Protea teammate Sigi Burger (goal shooter) at the same club, will be an advantage for both of us and for the Proteas as a combination.”

Rademan has had a great past two years, making her Protea debut (12 tests in total) and receiving a number of accolades, such as the Varsity Netball Player of the Tournament in 2019.

In the Telkom Netball League in October, captaining the Free State Crinums, she was named Shooter of the Tournament. She was Player of the Match twice. Her goal average of 88,1% was the highest in the competition.

“Last year was such a good year for me personally, but that remains in the past. You can’t become complacent. I want to keep working hard and become a much better player,” Rademan said.

 

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept